Johnson & Johnson (JNJ) announced new data from the Phase 3 Vivacity-MG3 study and ongoing open label extension in a broad population of antibody-positive adults with generalized myasthenia gravis reinforcing the efficacy, sustained disease control and safety profile of IMAAVY. Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+. Patients achieving sustained minimal symptom expression experienced greater improvements in quality of life than those with transient MSE in a post-hoc analysis of the Phase 3 study.
"As demonstrated in our pivotal trial, IMAAVY was shown to deliver sustained disease control in a broad population of people living with gMG, helping to address a critical unmet need," said Chris Gasink, Vice President, Medical Affairs, Autoantibody & Gastroenterology, Johnson & Johnson.
Johnson & Johnson previously announced plans to initiate EPIC in 2025. The study, comparing the efficacy of IMAAVY versus efgartigimod, is now enrolling participants.
In pre-market trading on NYSE, Johnson & Johnson shares are down 0.50 percent to $225.00.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.